Major pathologic response and long-term clinical benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative breast cancer after neoadjuvant chemotherapy

The majority of HR+/HER2-breast cancer patients can also achieve long-term survival despite not attaining pCR, indicating limited prognostic value of pCR in this population. This study aimed to identify novel pathologic end points for predicting long-term outcomes in HR+/HER2-breast cancer after neoadjuvant chemotherapy.